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Summary 
Development of diabetes in NOD mice is polygenic and dependent on both major histocompatibility 
complex (MHC)-linked  and non-MHC-linked  insulin-dependent  diabetes (Idd)  genes.  In (F, 
x  NOD) backcross analyses using the B10.H-2e7 or B6.PL-Thyl ~ strains  as the outcross partner, 
we previously identified several non-MHC Idd loci,  including  two located on chromosome 3 
(Idd3 and IddlO).  In the current  study, we report that  protection from diabetes is observed in 
NOD  congenic  strains  having  B6.PL-Thyl a-  or  B10-derived  alleles  at  Idd3  or  Idd10.  It  is 
important  to note that  only partial protection is provided by two doses of the resistance allele 
at either Idd3  or IddlO.  However, nearly complete protection  from diabetes is achieved  when 
resistance alleles are expressed at both loci. Development of these congenic strains has  allowed 
Idd3  to be localized between Ght2  and D3Mit6,  close to the 112 locus. 
T 
he nonobese diabetic (NOD) t mouse develops autoim- 
mune diabetes and is thought to be a relevant model of 
human insulin-dependent  diabetes mellitus (IDDM). Many 
features of diabetes are shared when comparing human IDDM 
with the disease developed by NOD mice (1, 2). In both spe- 
cies,  autoantibodies  and  T  ceils  specific  for  the  insulin- 
producing 3  cells in the pancreas  are detected (3-9).  It has 
been demonstrated that both CD4 + and CD8 + T  cells are 
required for the destruction of 3  cells in the NOD mouse 
(10-12).  In humans,  T  cell infiltrates  are found within the 
islets of Langerhans and are thought to mediate the autoim- 
mune destruction  (13-15). 
Disease development in the NOD mouse is complex and 
polygenic. A major genetic component of the disease is a gene 
(or genes) linked to the MHC,  termed IddI  in the mouse 
(16-18). The primary candidate genes for the MHC-linked 
diabetogenic loci are those which encode the ot and 3 chains 
of I-Ag 7 in NOD mice (19).  Evidence for the role of class 
II molecules comes from the observation that the transgenic 
introduction of an I-E ot gene into NOD mice, which results 
in the expression of I-E,  can completely protect from dia- 
betes as well as insulitis  (20, 21).  Similar protective effects 
1 Abbreviations used in thispaper: Idd, a gene controlling insulin-dependent 
diabetes; NOD, nonobese diabetic. 
have been observed with other I-A and I-E molecules intro- 
duced by transgenic  technology and conventional breeding 
strategies (21-25). One mechanism for disease protection by 
non-NOD class II molecules may be that presentation of au- 
toantigens by I-Ag 7 is less efficient  or nonexistent  (26),  or 
alternatively,  a  non-I-Ag 7 cell-specific nonpathogenic  im- 
mune response may actively suppress the I-AgT-restricted  re- 
sponse. 
Although diabetes is controlled by a number of genes in 
the NOD mouse, the individual contribution of each Idd locus 
can be ascertained using a series  of congenic NOD  mouse 
strains,  each possessing a resistance  allele at a single Idd locus. 
Such Idd congenic mice are produced by introgressing Idd- 
containing  chromosomal regions from normal nondiabetic 
mice into the genome of the NOD strain by repetitive back- 
crossing. We (24, 25, 27) and others (28, 29), developed MHC 
(Iddl)  congenic NOD mice,  such as NOD.H-2 b, NOD.H- 
2 "bl, and NOD.H-2 is, and found that  these mice are com- 
pletely protected from diabetes and insulitis.  By studying the 
F1 progeny of the Iddl  congenic strain  and NOD,  the in- 
heritance  of protection by one  dose  of an Idd allele can be 
established. In the case of (NOD.H-2 b x  NOD)F1 mice, in- 
sulitis is observed in ,,o50% of female mice, whereas diabetes 
develops in <5%  of female mice (24,  27). 
Our long-term goal is to define the inheritance  and bio- 
logic activity of other Idd loci using the same congenic mouse 
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The chromosomal locations of some of the non-MHC-linked 
loci influencing the development of diabetes  have been de- 
tected in humans and in the NOD mouse. In humans, one 
locus outside of the MHC has been shown to contribute to 
disease susceptibility, the insulin gene region on chromosome 
11p15 (30, 31). In a backcross analysis of (NON  x  NOD)Ft 
mice to the NOD parent, Idd2 on chromosome 9 was the 
first non-MHC locus identified that influenced the incidence 
of diabetes (17). Additional diabetogenic loci, Icld3, 4,5,6, 7,8,9, 
and 10, have been localized to chromosomes 3 (centromeric), 
11, l, 6, 7, 14, 4, and 3 (distal),  respectively, from a (B10.H- 
2g  7 x  NOD)Ft  x  NOD backcross  analysis (32-36).  It is 
interesting to note that NOD homozygosity is not always 
associated with increase risk of diabetes for all of the Idd loci. 
In the case ofldd7 and IddS, the B10 alleles are more diabeto- 
genic and homozygosity for the NOD allele at these loci is 
protective (33,  35). 
To characterize further the non-MHC-linked Icld loci, we 
describe  several new NOD congenic strains  which express 
the B10- or B6.PL-Thyla-derived  allele at Idd3 and/or IddlO. 
Results from these strains demonstrate that the non-NOD 
alleles at Idd3 and IddlO individually contribute to disease pro- 
tection, although protection is only partial. The combina- 
tion of resistance alleles at both Idd3 and IddlO on the NOD 
background results in profound disease protection. This study 
demonstrates the usefulness of NOD congenic strains of mice 
in the dissection of autoimmune diabetes. 
Materials and Methods 
Animals.  NOD/MrkTacfBR.  (NOD) mice were purchased from 
Taconic Farms Inc. (Germantown, NY) and C57BL/lOSnJ (B10) 
and B6.PL-ThyI~  (B6.PL-ThyI a) mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). The B6.PL-Thyl a congenic 
strain was derived at The Jackson Laboratory by backcrossing (B6 
x  PL)F1 mice to the C57BL/6  (B6) strain with selection for the 
PL Tttyl allele  on chromosome  9. All mice were housed  under sterile, 
specific pathogen-free conditions. NOD mice (K  d, I-A  sT, D b, and 
no expression of I-E) were outcrossed to B10 or B6.PL-Thyl ~ mice 
(both strains express K  b, I-A  b, and D b, and lack I-E expression) 
and the resulting F~ mice backcrossed to the NOD parental strain 
as reported earlier. First backcross mice were selected for homozy- 
gosity at the NOD MHC by testing for the expression of I-A  b 
and I-Ag  7 on the surface of PBMC as previously described (24). 
Further selection  criteria based on the development of diabetes and 
insulitis are described in Results. 
At the fifth or sixth backcross generation, DNA was isolated 
from peripheral blood leukocytes  of mice from pedigrees relatively 
resistant to diabetes and tested for the presence of genetic markers 
on chromosome 3. Mice expressing B10 or B6.PL-Thyl ~ alleles at 
various loci on chromosome 3 were selectively  bred and used to 
develop the congenic lines described in this study. All microsatellite 
markers, with the exception of D3Nds7 and D3Nds28, have been 
described previously (35-38). The oligonucleotide primer set for 
D3Nds7 is 5'-TGCTCCTCACCGTCA-TGC-Y and 5'-TAGTGT- 
TTGCCATGGCTCTC-Y and for D3Nds28  is 5'-GGTAGGAT- 
T:FGATGGAGGC-Y and  5'-TTCTGCAGCAGATGGGAAC-Y 
(Denny, P., and E. Hopes, personal communication). 
Assessment  of Diabetes and Insulitis.  Mice  were monitored for 
the development  of  diabetes by testing for elevated  levels of  urinary 
glucose with Tes-Tape (Eli Lilly,  Indianapolis, IN). Animals were 
classified  as diabetic after producing Tes-Tape  values  of 3 + or higher. 
We previously  demonstrated that elevated  urinary glucose  measure- 
ments with Tes-Tape/>1+ corresponded with blood glucose levels 
>320 mg/dl (39). Diabetic mice also displayed polydipsia, poly- 
uria, and weight loss. The presence of insulitis was assessed after 
fixation of pancreata in buffered 10% formalin and paraffin sec- 
tioning. Tissue sections (5 #m) were stained with hematoxylin  and 
eosin and examined for the presence of mononuclear cell infiltra- 
tion. Two noncontiguous sections of each tissue were examined. 
Classification  of  each animal  was made using the most severe  inflam- 
matory lesion observed. 
Cyclophospkamide 7~eatment.  Lyophilized  cytoxan  (cyclophospha- 
mide for injection, Mead Johnson Oncology Products, Evansville, 
IN) was prepared immediately before injection by adding sterile 
distilled water for a final  concentration of 20 mg/ml. Mice received 
200 mg/kg by i.p. injection on days  0 and 14. All mice were nondi- 
abetic before treatment and diabetes was monitored on a weekly 
basis up to day 29 after the first injection. 
Results 
Development of NOD  Congenic Strains.  The B10 and B6 
strains  of mice have previously been shown to possess four 
to five diabetes-resistant  loci (18, 29). To begin defining these 
loci, we developed  a series of NOD-related strains bred for 
diabetes-resistance after outcrosses to both the B10 and B6.PL- 
Thyl a strains.  We used the B6.PL-Thyl a strain rather than 
B6 in order to follow segregation of Idd2,  which is linked 
to the ThyI locus (17). At the first backcross generation, we 
selected nondiabetic mice that were homozygous for the NOD 
MHC, these mice were then continually backcrossed to the 
NOD strain with selection  for diabetes resistance. Diabetes 
resistance was defined as a lack of spontaneous or cyclophos- 
phamide-induced diabetes  and little or no insulitis.  Female 
mice at each backcross were assessed for resistance to cyclo- 
phosphamide-induced diabetes and insulitis after the produc- 
tion of at least two litters. Subsequently, in a backcross anal- 
ysis using the NOD and BIO.H-2 "~  strains,  we discovered 
that a region on chromosome 3 was a major determinant 
of diabetes susceptibility in the NOD mouse (33, 35). This 
linkage to diabetes  on chromosome 3 was also observed  in 
a backcross  analysis performed with the NOD and B6.PL- 
Thyl ~ strains (33,  36).  Two diabetes-resistant  strains  were 
still segregating a large section of  chromosome 3 derived from 
either B10  (at  the  sixth backcross  generation) or B6.PL- 
ThyI ~ (at the fifth backcross  generation). These two con- 
genie strains are described in this report as the NOD.Blff  12- 
rshb and NOD.B6 It2-rshb strains, respectively (Table 1). Using 
a battery of microsatellite markers which are polymorphic 
between NOD and B10 or B6.PL-Thyl ~ (35), we continued 
to backcross these two congenic strains and to screen progeny 
for additional recombination events on chromosome 3.  To 
facilitate the fine-mapping of the diabetes resistance gene on 
chromosome 3, such recombinant mice were used to initiate 
new congenic strains in which smaller portions of non-NOD 
chromosome 3 DNA were introgressed into the NOD ge- 
home (Table  1). 
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Congenic Strain 
0  Marker locus  NOD.B61~-r'hb*  NOD.B61t2s  NOD.B6 TM  NOD.B6  ~  NOD.B10  n2-T'hb**  NOD.B10r'hbt* 
D3Nds28  NOD  NOD  NOD  NOD  NOD  NOD 
0.053  D3Ndsl2 (Ght-2)  B6  B6  NOD  NOD  NOD  NOD 
0.053  D3Nds6 (112)  B6  B_66  NOD  NOD  B10  NOD 
0.046  D3Mit6  B6  B6  NOD  NOD  B10  NOD 
0.077  D3Ndsl  B6  B6  NOD  B6  B10  NOD 
0.053  D3Mit22  B6  B6  NOD  B6  B10  NOD 
0.038  D3Mit51  B6  B6  B6  B6  B10  NOD 
0.063  D3Mit40  B6  NOD  B6  NOD  B10  B10 
0.008  D3Nds7 (Cacy)  B6  NOD  B6  NOD  B10  B10 
0.037  D3Ndsll  (FcgrI)  B_66  NOD  B6  NOD  B10  B10 
0.008  D3MitlO  B6  NOD  B6  NOD  B10  B10 
0.022  D3Nds8 (Tshb)  B6  NOD  B_66  NOD  B10  B10 
0.217  D3Nds9 (Adh-1)  NOD  NOD  NOD  NOD  NOD  B10 
* The recombinant fraction between loci using data obtained from 60-132 animals. 
The NOD.B6.PL-Thyla D3Nds12 D3Nds8 (N6F3-5) strain. 
S  The NOD.B6.PL-Thyla D3Nds12 D3Mit51 (N7F2-3) strain. 
U  The NOD.B6.PL-Thyla D3Mit51 D3Nds8 (N7F3-5) strain. 
￿82  The NOD.B6.PL-Thyla D3Ndsl D3Mit51 (N10F2-4) strain. 
** The NOD.BIO-D3Nds6 D3Nds8 (N7F4-5) strain. 
** The NOD.BIO-D3Mit40 D3Nds9 (N7F4-5) strain. 
During the selection process,  congenic strains were ana- 
lyzed for the presence of other chromosomal regions known 
to  contribute to  diabetes  resistance  in  the  NOD  mouse, 
specifically Idd2, 4, 5, 6, 7, 8, and 9 (35). In addition, a panel 
of microsatellite markers sampling the entire genome were 
used to characterize  the congenic strains (35). Regions out- 
side of chromosome 3 that were detected as non-NOD were 
replaced  with the  NOD  alleles by selective breeding.  As 
detailed  later,  segregation  analysis  of  the  NOD.B6 It2-~hb 
strain has been performed and results are consistent with the 
hypothesis that  only regions  on chromosome 3  are  con- 
tributing to diabetes resistance.  It is also important to note 
that the statistical probability of achieving homozygosity at 
loci unlinked to the selected locus increases with the number 
of backcrosses performed. All of the congenic strains in the 
current report were studied at the N6, N7, or N10 genera- 
tions (see Table 1) in which there is a 96.9,  98.4, and 99.8% 
chance of homozygosity for the NOD  allele  at  unlinked 
loci (40). 
The NODB6 ~2-7"shb Strain  Shows Profound Protection from 
Diabetes.  Development of spontaneous diabetes in male and 
female NOD.B6  n2-~'shb mice was monitored for 7 mo (Fig. 
1, A and B, Table 2). Almost complete protection from dis- 
ease was observed in both female (Fig.  1 A) and male (Fig. 
1 B) NOD.B6  ne-rshb mice; only 2 of 159 (1.2%)  females and 
no males (0/145) developed spontaneous diabetes  (Table 2). 
This near lack of diabetes  is in marked contrast to the pa- 
rental frequency of disease observed in our NOD colony during 
this time: 78% in females and 38% in males (Fig. 1, Table 2). 
(NOD.B6 ~12-r'hb  x  NOD)F1  mice,  which possess  only 
one copy of the protective chromosome 3-derived DNA, 
showed a reduced, but significant, level of protection from 
diabetes  (Fig.  1, A  and B). Whereas the disease incidence 
was reduced by half in F1 females as compared with NOD 
females (41 vs. 78% incidence of diabetes at 7 mo; p <10-4), 
male (NOD.B6  ~le-T'hb x  NOD)F1 mice remained nearly dis- 
ease free at 7 mo with only 4 of 132 male F1 mice diabetic 
by this  time.  It is  striking that with (NOD.B6 ~-Tshb  x 
NOD)F1 mice, the usual twofold higher risk of disease de- 
velopment with NOD females compared with NOD males 
had increased to a 13-fold difference in disease incidence with 
41%  of females and 3%  of males  developing diabetes. 
The NOD.B6 ~t2 and NOD.B6 rshb Strains Have Higher Fre- 
quency of Diabetes than the NOD.B6 It2-rshb Strain.  Since the 
NOD.B6 m and NOD.B6 r'hb congenic strains essentially di- 
vide in half the region introgressed in the NOD.B6 xte-r~hb 
congenic strain (Table 1), we expected that one or the other 
of the two strains would resemble the NOD.B61e-rshb strain 
with respect  to diabetes incidence.  To our surprise,  neither 
strain showed the same pattern of protection from diabetes 
seen in NOD.B6 It2-T~hb mice.  In the case of the NOD.B6 tt2 
congenic strain (Fig.  1, C and D), male homozygotes were 
almost completely protected with only 1 of 84 mice developing 
diabetes. This value was not significantly different than the 
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Figure  1.  Development of diabetes in NOD congenic mice. (A) 159 NOD.B6 lt2-Tshb (A) and 118 (NOD.B61te-T~hb x  NOD)Ft (m) female mice 
were observed for the development of spontaneous diabetes. (B) 145 NOD.B61/2-T~hb (A) and 132 (NOD.B61/2-Tshb x  NOD-F1 (m) male mice were 
observed for the development of spontaneous diabetes. (C) 81 NOD.B61t2 (A) and 73 (NOD.B6112 x  NOD)FI (m) female mice were observed for 
the development of spontaneous diabetes. (D) 84 NOD.B6 I/2 (~k) and 77 (NOD.B6 I/2 x  NOD)Ft (m) male mice were observed for the development 
of spontaneous diabetes. (E) 62 NOD.B6 Tshb (A) and 78 (NOD.B6 Tshb x  NOD)F1 (I) female mice were observed for the development of sponta- 
neous diabetes. (F) 63 NOD.B6 T~hb (A) and 67 (NOD.B6 T'hb x  NOD)F1 (I) male mice were observed for the development of spontaneous diabetes. 
For comparison, the cumulative incidence of diabetes in 50 female (A, C, and E) and 49 male (B, D, and F) NOD mice is shown (Q). 
frequency observed in NOD.BC 12-T'hb males. In contrast, the 
frequency  of  diabetes  in  NOD.B6 I~2  females  (28%)  was 
significantly  higher  (p  <10 -4)  than  that  observed  in 
NOD.B6 m-T'hb females.  The  NOD.B6 Tshb congenic  strain 
(Fig. 1, E and F) showed a distinct pattern of protection from 
diabetes compared with the NOD.B6 m strain since both re- 
male and male NOD.B6 T'hb mice had a higher frequency of 
diabetes,  33  and  14%,  respectively, as compared with  the 
NOD.B6 m-r'hs congenic strain (p <10 -4 for both  sexes). 
The  NOD.B6 m  and  NOD.B6 rshb strains  also  produced 
different  patterns  of  diabetes  frequency  when  present  in 
(NOD.B6 m  x  NOD)Ft  and  (NOD.B6 T'hb  x  NOD)F1 
Table  2.  Incidence  of Diabetes in  NOD  Congenic  Strains 
Female incidence  p  value vs.  Male incidence  p  value vs.  male 
Strain  of diabetes*  female NOD*  of diabetes*  NOD* 
NOD.B6 a2-rs*b  2/159  (1.2%)  <10 -4  0/145  <10 -4 
NOD.B6 n2  23/81  (28.4%)  <10 -4  1/84  (1.2%)  <10 -4 
NOD.B6 T'hb  50/152  (32.9%)  <10 -4  19/137  (13.9%)S  <10 -4 
NOD.B6  ~  50/68  (73.5%)  >0.05  18/60  (30.0%)  >0.05 
NOD.BIO It2-r'hb  2/72  (2.8%)  <10 -4  0/87  <10 -4 
NOD.B10 r'~b  23/59  (39.0%)  <10 -4  4/76  (5.3%)  <10 -4 
NOD  63/81  (77.8%)  31/81  (38.3%) 
* The incidence of diabetes refers to the percentage of mice diabetic by 7 mo of age. 
* Determined  using Fisher's Exact Test. 
$ The diabetes incidence for NOD.B6 T'hb males was not significantly different than  the incidence for NOD.BIO r'hb males (p >0.05). 
1708  Genetic Control  of Diabetes mice,  respectively (Fig.  1,  C-F).  Female (NOD.B6  it2  x 
NOD)F1  mice were not protected from diabetes  whereas 
male (NOD.B6 n2  x  NOD)F1 mice were significantly pro- 
tected against disease at 7 mo of age (14/77 diabetic, p  = 
0.0078 vs NOD males). In contrast, for the (NOD.B6  TM  x 
NOD)F1 strain,  female mice were marginally protected from 
disease (48/78, p  =  0.0376 vs. NOD females) but males were 
not (17/67, p  =  0.1136 vs.  NOD  males). 
At Least Two Genes Account  for the Resistance to Diabetes in 
NODB6  n2-7"`hb Mice.  The patterns of diabetes resistance ob- 
served in the NOD.B6112-r'hb, NOD.B6 I12, and NOD.B6  TM 
strains led us to hypothesize that at least two linked loci on 
chromosome 3 accounted for the profound diabetes resistance 
of the NOD.B6 t12-r'hb congenic strain. Resistance alleles from 
the B6.PL-Thyl a strain at both loci were required for the 
near-complete resistance  to diabetes.  The reduced, but sig- 
nificant resistance to disease observed in the NOD.B6 I12 and 
NOD.B6  TM strains could then be explained by the fact that 
each of these strains expresses diabetes resistance via only one 
of the two loci active  in the NOD.B6 Ite-T~hb strain. To ad- 
dress this hypothesis, complementation studies were performed 
to determine if a combined activity of the putative resistance 
alleles could be observed. 
The  frequency  of  diabetes  in  (NOD.B6 n2  x 
NOD.B6T'hb)F1  mice  was  compared  with  those  of 
(NOD.B6 ae  x  NOD)F1,  (NOD.B6 TM  x  NOD)F1  and 
(NOD.B6  ae-Tshb  x  NOD)F1  mice (Fig.  2 A).  Remarkably, 
the frequency of diabetes in (NOD.B6 ne-r~hb x  NOD)F1 was 
equivalent  to  the  frequency  observed  in  (NOD.B6  a2  x 
NOD.B6rs~b)Ft mice; both of these F~ strains were protected 
significantly more than either the (NOD.B6 a2  x  NOD)F~ 
or (NOD.B6 TM  x  NOD)F~ strains  (p <0.006 for all com- 
parisons).  This observation supports the hypothesis outlined 
above  and  suggests  that  (NOD.BC  ~-r~h~  x  NOD)F~  and 
(NOD.B6 ~tz  x  NOD.B6r'~)F~  mice both have one dose of 
the B6.PL-Thy1~-derived protective  allele at each of the two 
loci (Idd3 for the centromeric locus  and IddlO for the distal 
locus).  In (NOD.B6 ne-r'h~  x  NOD)F~ mice,  the protective 
alleles are cis whereas in the (NOD.B6 ae  x  NOD.B6T,~)F1, 
the protective alleles are trans. 
Observations made with additional F~ strains support the 
two-gene hypothesis for chromosome 3 (Fig. 2 B). When two 
doses of the B6.PL-Thyl ~ allele at Idd3 were present,  as in the 
NOD.B6 ~  strain,  23/81  females developed diabetes.  How- 
ever, when one dose of the B6.PL-ThyI ~ allele at IddlO was 
present in addition to the two doses of the B6.PL-Thyl ~ al- 
lele at Idd3, as in the (NOD.B6 a2-T~  x  NOD.B6/t2)Fh fewer 
females developed disease (6/57, p  =  0.0116). Similarly, the 
NOD.B6  TM  strain,  which has two doses of the protective 
allele  at  IddlO, was  less protected  from  diabetes  than 
(NOD.B6 n2-r~  x  NOD.B6r~)F~ mice, which have a single 
dose of the protective allele at Idd3 in addition to two doses 
of the protective allele at Idd10 (50/152 vs. 9/61, p  =  0.007). 
It is interesting to  note that in female  (NOD.B6  a2-r'h~  x 
NOD.B6rs~)F~  mice, a single dose of the diabetes-resistance 
allele at Idd3 decreased the incidence of diabetes when it was 
expressed in the context of resistance at IddlO. A  protective 
effect from a single dose of this same Idd3 allele was not ob- 
served in the context of the NOD background in females (see 
[NOD.B6 It2  x  NOD]F1  vs.  NOD  in Fig.  1 C). 
Localization ofldd3 and Idd10.  The lack of complete pro- 
tection in the presence of one or two doses of the protective 
B6.PL-ThyI a allele at Idd3 or IddlO makes fine-mapping of ei- 
ther locus by backcross analysis  impossible. We therefore selected 
a strategy in which informative recombination events were 
fixed on the NOD background and a sufficient number of 
homozygous mice were examined for their incidence of dia- 
betes. In this way, protection from diabetes by Idd3 and IddlO 
could be localized to smaller regions of chromosome 3. The 
NOD.B6  ~  strain is an example of such a congenic (Table 
1). This mouse was derived from the NOD.B6 n2 strain after 
an outcross to NOD and subsequent hackcrossing to the NOD 
parent.  A recombination event occurred between D3Ndsl  and 
D3Mit6 during a backcross meiosis. The event was fixed by 
backcrossing the recombinant mouse to the NOD strain once 
again in order to produce male and female mice possessing 
the recombination event. Intercrossing such heterozygous mice 
produced  the  homozygous founders of the  NOD.B6  ~ 
strain  in which B6.PL-Thyl~-derived  alleles are  present  at 
D3Ndsl,  D3Mit22,  and D3Mit51. 
It is interesting to note that the NOD.B6  D3N~I strain was 
not protected from diabetes (Table 2). This result places Idd3 
centromeric of D3Ndsl  and IddlO telomeric of D3Mit51. We 
next took advantage of the results from NOD mice congenic 
for regions on chromosome 3 derived from the B10 strain to 
localize further Idd3 and IddlO (Table 1).  It is highly likely 
that the B10 and B6.PL-Thyl a strains  have the same alleles 
at both Idd3 and IddlO since the B6 and B10 strains diverged 
only within the past 40 yr. In addition, the two strains have 
been shown to be identical at 101 of the 102 microsatellite 
sequences  tested (32). Moreover,  the frequency  of diabetes 
is indistinguishable between the NOD.B10  n2-~'hb strain  and 
the NOD.BC  t2-:rshb strain  (Table 2).  Similarly, the frequency 
of diabetes in NOD.B10  TM and NOD.B6  TM mice is not sig- 
nificantly different (Table 2). 
Since the NOD.B10  n2-T~hb strain has fixed a recombination 
event between D3Nds6  and D3Nds12(Table 1), but still re- 
mains profoundly diabetes resistant,  Idd3 must be telomeric 
of D3Nds12. Similarly, the protection from diabetes observed 
in  NOD.B10  TM  mice  places IddlO telomeric of D3Mit51, 
Taking advantage  of the mapping information from all the 
strains  listed in Table 1, Idd3 is located in a region of ~10 
cM between (but not including) D3Nds12 and D3Ndsl, and 
IddlO is located in a region of ,'o34 cM between (but not in- 
cluding) D3Mit51 and D3Nds9. 
Resistance to Diabetes in NODB6  n2-Tshb Mice Segregates with 
Chromosome 3.  To ensure that regions outside of chromo- 
some 3 were not contributing to the results reported, we 
performed a  segregation analysis with the NOD.B6 II2-T~hb 
congenic  strain.  (NOD.BC  t2-r~hb  x  NOD)Ft  mice  were 
backcrossed  to NOD mice and the resulting progeny were 
monitored for diabetes.  The incidence of disease was 52% 
for females (72/139)  and 22% for males (32/147)  at 6 mo 
of age, which is only slightly less than the 6 mo incidence 
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Figure  2.  At least two genes on chromosome 3 influence the develop- 
ment of diabetes. (A) 73 (NOD.B6 ~  x  NOD)F1 (@), 78 (NOD.B6 TM x 
NOD)F1 (I),  118 (NOD.B6 t~-r'hb  x  NOD)F1  (A), and 70 (NOD.B6 m 
x  NOD.B6rshb)F1 (O) female  mice were monitored for the development 
of  diabetes.  (B)  62  NOD.B6 TM  (0),  81  NOD.B6 H2  (I),  61 
(NOD.B6/le-Tshb  x  NOD.B6T~hb)F1  (O),  57  (NOD.B6//e-T'hb  x 
NOD.B6n2)F1  ([S]),  and  159  NOD.B6 ~/2-T~hb (A) female mice were ob- 
served for diabetes. Schematics representing  the chromosomal regions con- 
tributed by the B6.PL-Thyl a strain  are shown. 
of diabetes in our NOD  colony, 74%  for females and 28% 
for males (Fig. 1). Although a control group of 36 backcross 
mice  showed  the  expected  distribution  of  F1  and  NOD 
genotypes of 112 (17 Ft and 19 NOD  types at D3Nds6) and 
Tshb (15  F1  and  21  NOD  types  at D3Nds8),  the  diabetic 
mice were enriched for NOD homozygosity at 112 and Tshb. 
Only slight enrichment of NOD homozygosity was observed 
among 49 female diabetics genotyped ifll2 and Tshb loci were 
considered separately;  30 of the diabetics were NOD at Tshb 
(61%) and 28 were NOD at 112 (57%). However, consistent 
with the presence of two diabetes resistance genes on chro- 
mosome 3,  only  13  of the 49 female diabetics  typed were 
F1 at both 112 and Tshb (27%). Among the 19 male diabetics 
analyzed,  a greater  enrichment of NOD homozygosity was 
observed as compared with  the female diabetics;  15 of the 
diabetics were NOD  at  Tshb (79%)  and 16 were NOD  at 
112 (84%).  Only 2 of the 19 diabetic backcross males were 
F1 at both 112 and Tshb. The high incidence of diabetes  in 
this backcross generation  and the results of the genotypic 
analysis support the hypothesis that B6.PL-Thyl"-derived  al- 
leles located on chromosome 3 are the primary (or only) source 
of diabetes resistance  in the NOD.B6 zlz-~hb congenic strain. 
Insulitis  and  Cyclophosphamide-induced  Diabetes  in 
NODB6 n2-T'hb, NODB6~ and NOD.B6  TM Mice.  Pancreata 
obtained from female and male NOD.B6112-r'hb, NOD.B6 Iu, 
and NOD.B6 TM mice were examined at 2 and 5 mo of age 
for the presence of insulitis (Fig.  3, A  and B).  Despite  the 
profound resistance to diabetes, insulitis was observed in the 
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Figure  3.  Incidence ofinsulitis and cyclophosphamide-induced  diabetes 
in chromosome 3 congenic mice.  The percentages  of females  and males 
(9-16 mice per group) with mild to severe insulitis at 2 and 5 mo of age 
are shown in A  and B,  respectively.  In C, nondiabetic  mice >7 mo of 
age (17-35 mice per group) were treated with cyclophosphamide  as detailed 
in  Materials  and  Methods  and  monitored  for  the  development  of 
cyclophosphamide-induced  diabetes. 
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only 1/10 males and 0/10 females examined at 2 mo of age 
as compared with 7/10 (p  =  0.02) and 10/11 (p <10 -4) age- 
and  sex-matched  NOD  mice.  With  time,  however,  more 
NOD.B6  It2-Tshb mice  developed insulitis;  at  5  mo  of age, 
4/16 females and 2/16  males had insulitis  (Fig.  3 B).  The 
insulitis appeared to have/3 cell-specific cytotoxic potential 
since treatment of NOD.BC  tz-rs~b mice at 7 mo of age with 
cyclophosphamide caused diabetes in 3/35 females and 7/28 
males  (Fig.  3  C). 
Since the  NOD.BC  12 and  NOD.B6  TM  strains  present  a 
higher frequency of diabetes than the NOD.B6 zte-7"shb strain 
(Fig.  1),  it was not unexpected that  more NOD.B6  I12 and 
NOD.B6 TM mice developed insulitis by 2 and 5 mo than 
did NOD.B61t2-r~hb mice (Fig.  3).  Consistent  with  the ex- 
pression of insulitis,  was the observation that the NOD.B6  ne 
and  NOD.B6 TM  strains  developed  cyclophosphamide- 
induced diabetes (Fig.  3  C). 
The results with the NOD.B6 m and NOD.B6 T~hb strains, 
expressing resistance alleles at Idd3 and Idd10, respectively, sug- 
gest that resistance alleles at each of these two Idd loci reduce 
the frequency of insulitis.  However, when resistance alleles 
are present  at both loci,  as they are in the NOD.B6 ne-rshb 
strain,  the reduction of insulitis is even more profound. This 
suggests that Idd3 and IddlO act early in the disease process, 
during  the development  of insulitis.  However, since some 
NOD.B6 m-rshb mice develop insulitis  and  a small number 
develop spontaneous diabetes, the initiation  of the autoim- 
mune response to the/3 cells can occur in the absence of NOD 
alleles at both Idd3 and IddlO. 
Discussion 
Several years ago at the beginning  of the present study, we 
expected to  find  three  or four dominant-acting  and fully 
penetrant  protective alleles from the B10 and B6.PL-Thyl a 
backgrounds. Previous segregation analyses with the B10 (18) 
and  B6  (41)  strains  had  demonstrated  potent  protective 
influences from these normal mice, consistent with the exis- 
tence of what  appeared to be fully recessive  NOD-derived 
diabetes susceptibility loci.  Our initial  strategy to identify 
protective B10 or B6.PL-Thyl a alleles at non-MHC-linked 
diabetogenic  loci  was  to  backcross  (B10  x  NOD)Ft  or 
(B6.PL-ThyI"  x  NOD)F1 mice to the NOD parental strain 
and select for pedigrees demonstrating  a low frequency of 
diabetes.  We  hypothesized  that  each  dominant  diabetes- 
resistant allele derived from B10 or B6.PL-Thyl ~ would re- 
duce diabetes by 50%. We bred 23 different pedigrees to en- 
sure that  each of the proposed dominant  protective alleles 
would be responsible for disease  protection in at least one 
of the lines.  However, with  this  strategy, we were unable 
to demonstrate  the existence of any single dominant  allele 
from the B10 or B6.PL-Thyl a strains that protected against 
diabetes. Indeed, the eventual development of the congenic 
lines described in the present study, which were initiated with 
the above strategy, relied primarily on the fortuitous obser- 
vation that male mice were protected from diabetes. In retro- 
spect,  this protection was dependent on the pedigrees not 
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recombining between the two linked Idd loci on chromo- 
some 3, Idd3 and IddlO. Unfortunately, by the time we real- 
ized that many Idd loci were segregating in the (Bt0.H-2g  7 x 
NOD)  x  NOD  and  (B6.PL-Thyl a  x  NOD)  x  NOD 
backcrosses (33), only two pedigrees remained, eventually be- 
coming the NOD.BIO  m-rshb and NOD.B6  zt2-Tsht strains,  the 
other pedigrees were discarded because diabetes resistance could 
not be maintained. 
The development ofldd3 and Iddlo congenic strains of mice 
has provided a number of insights into the contribution of 
non-MHC-linked genes to autoimmune diabetes in the NOD 
mouse. The first, and perhaps most striking finding revealed 
by the congenic strains,  was that  two independent Idd loci 
exist on chromosome 3. Our initial mapping studies pointed 
to a single locus located near D3Ndsl, termed Idd3 (33). In 
that study, there was less than a 1 in 1,000 likelihood of finding 
Idd3 near I12. We now realize that the initial localization of 
Idd3 to D3Ndsl was caused by the combined effects of two 
Idd loci, Idd3 and IddlO, flanking D3Ndsl. In fact, a D3Ndsl 
NOD congenic strain is not protected from diabetes (Table 
2). A second striking finding from the Idd3 and IddlO con- 
genic strains was that  one or two doses of either resistant 
allele only partially protects from diabetes. Thus, at least in 
the case of Idd3 and IddlO, NOD alleles  at these loci con- 
tribute to, but are not absolutely required for, disease devel- 
opment. This is in contrast to NOD strains congenic for resis- 
tant alleles at Iddl where complete resistance to diabetes occurs 
with two doses of the resistant MHC allele and virtually com- 
plete resistance with  one dose (24,  25,  28,  29). 
Our goal of identifying the gene products of Idd3 and IddlO 
is made more difficult by the observation that the presence 
of the NOD allele at either locus is not absolutely required 
for diabetes. Thus, fine-mapping these two Idd loci using con- 
ventional segregation analyses is not possible. We have therefore 
begun to fine-map Idd3 and Idd10 by identifying potentially 
informative recombination events and developing new Idd3 
and IddlO congenic strains with smaller introgressed regions. 
Such studies are ongoing and the strategy has been successful 
at defining smaller chromosomal regions that contain Idd3 
and Idd10 (our unpublished  observations). 
There are several candidate genes for Idd3 and IddlO. One 
candidate gene for Idd3, Ght2, has been ruled out in the cur- 
rent study since a congenic strain expressing the NOD allele 
at Glut2 is resistant to diabetes (Tables I and 2). It is interesting 
to note that 112, which is polymorphic between NOD and 
the B10 and B6 strains  (35, 42), remains  a candidate gene 
for Idd3. However, despite this polymorphism in the struc- 
tural gene, no functional polymorphism of the lymphokine 
has been detected (42). Fcgrl, which encodes the high affinity 
Fc receptor and for which the NOD strain  has a rare mu- 
tated allele encoding a defective receptor (36), remains a can- 
didate gene for IddlO. Other noteworthy candidate genes for 
IddlO are Csfm and  Cd53. 
We speculate that, for several of the Idd loci that contribute 
to disease, the diabetes-susceptibility allele will often be found 
among inbred strains of mice because it alone does not confer 
disease susceptibility.  These diabetogenic allelic variants could 
alter lymphocyte homing, the physiology of beta cells within the islets, the establishment of peripheral tolerance, Thl/Th2 
balance, or other aspects of the autoimmune response. This 
model predicts that overlapping, but different sets of Idd loci 
will be found to segregate depending on the strain that is 
used to outcross with the NOD.  Each nondiabetic inbred 
strain tested would have a different pattern of alleles at the 
loci that contribute to the development of diabetes.  For ex- 
ample, in an (SWR  x  NOD)  x  NOD backcross analysis, 
no linkage of diabetes to chromosome 3 was detected (Leiter, 
E.,  personal communication). 
Finally, the development ofldd congenic strains allows gene 
interactions to be identified. For example, we found that the 
simultaneous presence of Idd3 and IddIO confers more resis- 
tance from diabetes and insulitis than would be expected from 
the protection provided by either locus alone. Thus, protec- 
tion caused by these two Idd loci appears to be synergistic 
rather than additive. It is interesting that a statistical evalua- 
tion of the contribution of Idd loci to the development of 
diabetes in the NOD mouse demonstrated that a multiplica- 
tire epistasis  model provides the best description of the ob- 
served disease  frequency (43).  The molecular basis  for the 
interaction between Idd3  and Idd10 must  await the identi- 
fication of these two genes and their biologic function in 
autoimmunity. 
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